Literature DB >> 8873317

Management of ductal carcinoma in situ.

M S Talamonti1.   

Abstract

The management of ductal carcinoma in situ (DCIS) is one of the most controversial topics in the treatment of breast cancer. With the introduction and utilization of screening mammography, clinically occult or microscopic DCIS has become the most frequent presentation of this disease. Recent advances in the characterization of DCIS according to histologic subgroupings, size and extent of disease, and nuclear grade have provided important information regarding the natural history of this heterogeneous group of lesions. Critical issues such as multicentricity, occult invasion, and potential for local recurrence and axillary metastases have been addressed in recent series. Prospective, single institution trials and data from the National Surgical Adjuvant Breast and Bowel Project (NSABP-B17) protocol have demonstrated that in many patients with mammographically detected DCIS, mastectomy may be over-treatment. Treatment issues for DCIS now focus on the clinical selection process to identify patients best suited for wide local excision alone vs. wide local excision and breast irradiation.

Entities:  

Mesh:

Year:  1996        PMID: 8873317     DOI: 10.1002/(SICI)1098-2388(199609/10)12:5<300::AID-SSU4>3.0.CO;2-H

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  3 in total

1.  Is mastectomy overused? A call for an expanded research agenda.

Authors:  Paula V Lantz; Judith K Zemencuk; Steven J Katz
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

2.  Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy.

Authors:  Firas Al-Zubaydi; Dayuan Gao; Dipti Kakkar; Shike Li; Jennifer Holloway; Zoltan Szekely; Nancy Chan; Shicha Kumar; Hatem E Sabaawy; Susan Love; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2021-02-15       Impact factor: 4.617

3.  Evaluation of intraductal delivery of poly(ethylene glycol)-doxorubicin conjugate nanocarriers for the treatment of ductal carcinoma in situ (DCIS)-like lesions in rats.

Authors:  Zichao Gu; Firas Al-Zubaydi; Derek Adler; Shike Li; Steven Johnson; Puja Prasad; Jennifer Holloway; Zoltan Szekely; Susan Love; Dayuan Gao; Patrick J Sinko
Journal:  J Interdiscip Nanomed       Date:  2018-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.